Getting diagnosed with endometriosis can be a long and frustrating journey. The disease is typically diagnosed between ages 25-35. By then, however, many patients have suffered from symptoms for a shocking 4-11 years.

This delay can have a significant impact on a woman's life. Beyond chronic and acute pain, the delay can contribute to fertility issues, and impact the overall life course. Delayed diagnosis can affect education, career, and relationships. This is why earlier diagnosis, and non-invasive diagnostic tools are crucial.

Several factors contribute to the delay. Many people, including healthcare providers, lack sufficient knowledge about endometriosis. Painful periods are often dismissed as “normal”, leading women to suffer in silence. Symptoms can be mistaken for other conditions, causing delays in getting the right diagnosis.

Doctors rely on a combination of patient history, symptoms, clinical examination, and imaging (ultrasound or MRI) for diagnosis. However, a definitive diagnosis currently requires laparoscopy, an invasive procedure.

A 2020 UK survey demonstrated in numbers the impact of delay in diagnostics for both patients and the healthcare system: 58% of women with endometriosis visited their GP over 10 times before diagnosis. 43% saw hospital doctors more than 5 times. 53% ended up in the emergency room.

Let's work together to shorten the endometriosis diagnosis journey.

Gesynta Pharma is dedicated to the development of better treatments for endometriosis patients, with promising preclinical data for vipoglanstat and a phase II study coming.